Abstract
Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1b antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study N Ruperto, H Brunner, G Horneff, P Quartier, T Constantin, Y Berkun, M Erguven, T Kallinich, R Brik, NM Wulffraat, MA Ferrandiz, L Rutkowska-Sak, H Ozdogan, L McCann, K Lheritier, R Preiss, L Tseng, A Martini, DJ Lovell, For the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Highlights
At Day 15, canakinumab was superior to placebo for the primary and secondary endpoints: ACR Ped30, 83.7 vs 9.8%; ACR Ped50, 67.4 vs 4.9%; ACR Ped100, 32.6% vs 0, respectively
ACR Ped30/50 responses with canakinumab remained significantly higher than with placebo at Day 29
Two non-fatal serious Adverse events (AEs) were reported in each group
Summary
Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1b antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study. N Ruperto1*, H Brunner, G Horneff, P Quartier, T Constantin, Y Berkun, M Erguven, T Kallinich, R Brik, NM Wulffraat, MA Ferrandiz, L Rutkowska-Sak, H Ozdogan, L McCann, K Lheritier, R Preiss, L Tseng, A Martini, DJ Lovell, For the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. 14-18 September 2011
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
